Meta-analysis of 14 studies (16,116 patients) in HR+/HER2- breast cancer: abemaciclib plus endocrine therapy improved PFS (HR 0.54) and IDFS (HR 0.68) vs endocrine therapy alone; OS was not significant (HR 0.86); most adverse events rose.
Meta-analysisn = 16,116
Sadia et al. Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR + and HER2-negative breast cancer; a systematic review and meta-analysis